The invention is directed to isomeric mixtures of cyclosporine analogues that are structurally similar to cyclosporine A. The mixtures possess enhanced efficacy and reduced toxicity over the individual isomers and over naturally occurring and other presently known cyclosporines and cyclosporine derivatives. Embodiments of the present invention are directed toward cis and trans-isomers of cyclosporin A analogs referred to as ISA
TX
247, and derivatives thereof. ISA
TX
247 isomers and alkylated, arylated, and deuterated derivatives are synthesized by stereoselective pathways where the particular conditions of a reaction determine the degree of stereoselectivity. Stereoselective pathways may utilize a Wittig reaction, or an organometallic reagent comprising inorganic elements such as boron, silicon, titanium, and lithium. The ratio of isomers in a mixture may range from about 10 to 90 percent by weight of the (E)-isomer to about 90 to 10 percent by weight of the (Z)-isomer, based on the total weight of the mixture.
本发明涉及与
环孢霉素A结构相似的
环孢霉素类似物的异构混合物。这些混合物具有比单个异构体和天然存在的及其他目前已知的
环孢霉素和
环孢霉素衍
生物更高的功效和降低的毒性。本发明的实施例涉及被称为I
SATX247的
环孢霉素A类似物的顺反异构体及其衍
生物。通过立体选择性途径合成I
SATX247异构体和烷基化、芳基化和
氘代衍
生物,其中反应的特定条件决定立体选择性的程度。立体选择性途径可以利用Wittig反应或包含
硼、
硅、
钛和
锂等无机元素的有机
金属试剂。混合物中的异构体比例可以从(E)-异构体的约10至90重量百分比到(Z)-异构体的约90至10重量百分比,基于混合物的总重量。